News | November 14, 2022
Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The acquisition is for an enterprise value of Rs. 218 crores
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
Subscribe To Our Newsletter & Stay Updated
